- Home
- ASM vs PHAT Comparison
ASM vs PHAT Comparison
Compare ASM & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- PHAT
- Stock Information
- Founded
- ASM 1968
- PHAT 2018
- Country
- ASM Canada
- PHAT United States
- Employees
- ASM N/A
- PHAT N/A
- Industry
- ASM Metal Mining
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- ASM Basic Materials
- PHAT Health Care
- Exchange
- ASM Nasdaq
- PHAT Nasdaq
- Market Cap
- ASM 348.1M
- PHAT 289.0M
- IPO Year
- ASM N/A
- PHAT 2019
- Fundamental
- Price
- ASM $2.56
- PHAT $3.12
- Analyst Decision
- ASM Strong Buy
- PHAT Strong Buy
- Analyst Count
- ASM 2
- PHAT 5
- Target Price
- ASM $2.00
- PHAT $17.80
- AVG Volume (30 Days)
- ASM 4.0M
- PHAT 1.7M
- Earning Date
- ASM 05-13-2025
- PHAT 05-01-2025
- Dividend Yield
- ASM N/A
- PHAT N/A
- EPS Growth
- ASM 1287.60
- PHAT N/A
- EPS
- ASM 0.06
- PHAT N/A
- Revenue
- ASM $66,178,000.00
- PHAT $81,859,000.00
- Revenue This Year
- ASM $22.93
- PHAT $201.74
- Revenue Next Year
- ASM $25.22
- PHAT $114.16
- P/E Ratio
- ASM $43.18
- PHAT N/A
- Revenue Growth
- ASM 50.78
- PHAT 3055.70
- 52 Week Low
- ASM $0.72
- PHAT $2.21
- 52 Week High
- ASM $2.57
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- ASM 71.07
- PHAT 25.16
- Support Level
- ASM $2.09
- PHAT $4.06
- Resistance Level
- ASM $2.57
- PHAT $4.45
- Average True Range (ATR)
- ASM 0.13
- PHAT 0.34
- MACD
- ASM 0.03
- PHAT -0.15
- Stochastic Oscillator
- ASM 90.97
- PHAT 3.57
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.